News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
824,692 Results
Type
Article (85283)
Company Profile (624)
Press Release (738785)
Section
Business (231883)
Career Advice (4091)
Deals (39623)
Drug Delivery (106)
Drug Development (90444)
Employer Resources (192)
FDA (17892)
Job Trends (17246)
News (394676)
Policy (39586)
Tag
Academia (2973)
Africa (1263)
Alliances (56346)
Alzheimer's disease (1250)
Approvals (17802)
Arizona (210)
Artificial intelligence (86)
Asia (49011)
Australia (8618)
Bankruptcy (392)
Best Places to Work (12266)
Biotechnology (438)
C2C Services and Suppliers (95111)
California (2062)
Canada (960)
Cancer (556)
Career advice (3498)
Cell therapy (145)
China (159)
Clinical research (70476)
Collaboration (160)
Colorado (88)
Compensation (85)
Connecticut (86)
COVID-19 (2756)
Cystic fibrosis (78)
Data (326)
Diabetes (92)
Diagnostics (6504)
Drug pricing (86)
Earnings (93535)
Employer resources (162)
Europe (112061)
Events (125044)
Executive appointments (167)
FDA (18132)
Florida (278)
Funding (158)
Gene therapy (110)
GLP-1 (623)
Government (5011)
Healthcare (20656)
Hotbed/Location (534575)
Illinois (324)
Indiana (163)
Infectious disease (2790)
Inflammatory bowel disease (103)
Interviews (804)
IPO (17499)
Job creations (5172)
Job search strategy (2850)
Kansas (100)
Layoffs (468)
Legal (10014)
Lung cancer (127)
Manufacturing (105)
Maryland (439)
Massachusetts (1743)
Medical device (14271)
Medtech (14276)
Mergers & acquisitions (21969)
Metabolic disorders (304)
Michigan (138)
Minnesota (236)
Neuroscience (1421)
New Jersey (625)
New York (631)
NextGen Class of 2024 (7622)
Non-profit (5054)
North Carolina (706)
Northern California (853)
Obesity (181)
Ohio (111)
Opinion (234)
Patents (83)
Pennsylvania (603)
People (63739)
Pharmaceutical (119)
Phase I (21639)
Phase II (30597)
Phase III (23118)
Pipeline (116)
Podcasts (76)
Postmarket research (3532)
Preclinical (9774)
Radiopharmaceuticals (251)
Rare diseases (143)
Real estate (7363)
Recruiting (72)
Regulatory (25613)
Research institute (2633)
Resumes & cover letters (645)
South America (1641)
Southern California (795)
Startups (4273)
Texas (272)
United States (9511)
Vaccines (570)
Washington State (284)
Weight loss (173)
Date
Today (91)
Last 7 days (661)
Last 30 days (2578)
Last 365 days (39856)
2024 (28355)
2023 (42566)
2022 (53929)
2021 (58727)
2020 (57671)
2019 (51341)
2018 (39125)
2017 (37193)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36269)
2012 (38416)
2011 (38383)
2010 (39616)
There are 824,692 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
BioHarvest Sciences Reports Director’s Ongoing Key Role Following Resignation from Board
September 20, 2024
·
2 min read
Press Releases
NervGen Pharma to Present at the Unite 2 Fight Paralysis 19th Annual Science & Advocacy Symposium Focused on Spinal Cord Injury
September 20, 2024
·
6 min read
Cancer
ADCs, Bispecifics and Radiopharma Take Center Stage at ESMO24
The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer treatment—antibody-drug conjugates, bispecifics and radiopharmaceuticals—while anti-TIGIT therapies made a bit of a comeback.
September 20, 2024
·
3 min read
·
Greg Slabodkin
RayzeBio
We are building a vertically integrated radiopharmaceutical therapeutics company with our lead program in a Phase 3 clinical trial. We believe we have established a leadership position in the emerging radiopharmaceutical therapeutics modality through a product-centric approach and have created a pipeline of multiple drug and development candidates in therapeutic areas with significant market opportunities.
September 20, 2024
FDA
FDA Tracker: J&J Scores Third NSCLC Approval for Rybrevant This Year
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as
BioSpace
keeps you up to date on all of the FDA’s decisions in 2024.
September 20, 2024
·
180 min read
·
Heather McKenzie
Weight Loss
Novo’s Next-Gen CB1 Drug Leads to Weight Loss in Phase II, but Neuropsychiatric Events Reported
Novo Nodrisk’s cannabinoid receptor–targeting obesity pill was picked up in the $1.1 billion acquisition of Inversago Pharmaceuticals last year.
September 20, 2024
·
2 min read
·
Annalee Armstrong
Press Releases
Stryker completes acquisition of NICO Corporation, expanding minimally invasive solutions for brain tumor removal and stroke care
September 20, 2024
·
2 min read
Press Releases
Singular Genomics Receives Non-Binding Acquisition Proposal from Concentra Biosciences and Tang Capital
September 20, 2024
·
4 min read
Press Releases
Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade
September 20, 2024
·
11 min read
Press Releases
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed
September 20, 2024
·
3 min read
1 of 82,470
Next
